UCB confirms third quarter Zyrtec sales in the US / 6% Increase in European Allergy Franchise
Brussels, 20 October 2004 - Following Pfizer's quarterly earnings release, UCB confirms that Zyrtec strengthened its leadership position as the number one most prescribed branded antihistamine in the US in new prescriptions. The US sales of Zyrtec have reached $ 938 million over the 9 months ending September 30th, 2004. This anticipated decrease of 4% against the same period in 2003 compares to a decreasing market of 16% (New prescriptions YTD).
In Europe, UCB's total allergy franchise increased by 6% for the same period thanks to the continued growth of Xyzal, which was launched in 2001.
Stay up-to-date on the latest news and information from UCB